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Abstract
Background: Even though in situ breast cancer (BCIS) accounts for a large proportion of the breast cancers
diagnosed, few studies have investigated potential risk factors for BCIS. Their results suggest that some established
risk factors for invasive breast cancer have a similar impact on BCIS risk, but large population-based studies on
lifestyle factors and BCIS risk are lacking. Thus, we investigated the association between lifestyle and BCIS risk within
the European Prospective Investigation into Cancer and Nutrition cohort.
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Methods: Lifestyle was operationalized by a score reflecting the adherence to the World Cancer Research Fund/
American Institute for Cancer Research (WCRF/AICR) cancer prevention recommendations. The recommendations
utilized in these analyses were the ones pertinent to healthy body weight, physical activity, consumption of plant-
based foods, energy-dense foods, red and processed meat, and sugary drinks and alcohol, as well as the
recommendation on breastfeeding. Cox proportional hazards regression was used to assess the association
between lifestyle score and BCIS risk. The results were presented as hazard ratios (HR) and corresponding 95%
confidence intervals (CI).
Results: After an overall median follow-up time of 14.9 years, 1277 BCIS cases were diagnosed. Greater adherence
to the WCRF/AICR cancer prevention recommendations was not associated with BCIS risk (HR = 0.98, 95% CI 0.93–
1.03; per one unit of increase; multivariable model). An inverse association between the lifestyle score and BCIS risk
was observed in study centers, where participants were recruited mainly via mammographic screening and
attended additional screening throughout follow-up (HR = 0.85, 95% CI 0.73–0.99), but not in the remaining ones
(HR = 0.99, 95% CI 0.94–1.05).
Conclusions: While we did not observe an overall association between lifestyle and BCIS risk, our results indicate
that lifestyle is associated with BCIS risk among women recruited via screening programs and with regular
screening participation. This suggests that a true inverse association between lifestyle habits and BCIS risk in the
overall cohort may have been masked by a lack of information on screening attendance. The potential inverse
association between lifestyle and BCIS risk in our analyses is consistent with the inverse associations between
lifestyle scores and breast cancer risk reported from previous studies.
Keywords: In situ breast cancer, Cohort, Lifestyle, Prevention, Lifestyle Score
Background
In situ breast cancer (BCIS) is an intraepithelial lesion
with malignant potential. Generally, it is considered a
non-obligatory precursor or a potential risk factor for in-
vasive breast cancer. Women with BCIS rarely report
symptoms, and the majority of in situ tumors are de-
tected through organized or opportunistic mammo-
graphic screening attendance [1].
Even though BCIS accounts for up to 20% of the
breast cancer cases diagnosed [2], its prognosis and
possible etiological similarities with invasive breast
cancer remain unclear. In epidemiological studies on
breast cancer risk, in situ tumors are often excluded
[3], censored [4], or included together with invasive
tumors as a composite endpoint [5]. Only few studies
have investigated potential risk factors for BCIS sug-
gesting that some established risk factors for invasive
breast cancer have a similar impact on BCIS risk [6–
9]. Regarding lifestyle factors, alcohol consumption
and smoking were found to be associated with a non-
statistically significant trend for increased risk of BCIS
in postmenopausal women [6], whereas higher body
mass index (BMI) was associated with a statistically
significant decreased risk for BCIS in premenopausal
women [7]. Physical activity studies showed mixed
findings, with some reporting no association with
BCIS risk [10, 11], while others reported an inverse
association [12]. However, comprehensive analyses on
pre-diagnostic diet and lifestyle in relation to BCIS
from large-scale cohort studies are sparse.
Considering the abovementioned studies suggesting an
inverse association of a more health-conscious lifestyle
with a decreased risk of BCIS, and the lack of large epi-
demiological studies, we investigated the association be-
tween lifestyle, operationalized by a score reflecting the
adherence to cancer prevention recommendations, and
BCIS risk within the European Prospective Investigation
into Cancer and Nutrition (EPIC) cohort.
Methods
Study population and data collection
EPIC is a multicenter prospective cohort study designed
to investigate the associations between diet, lifestyle,
genetic and environmental factors, and the incidence of
cancers and other chronic diseases. Over 520,000 partici-
pants, aged 25–70 years, were recruited between 1992
and 2000 in 10 European countries (Denmark, France,
Germany, Greece, Italy, the Netherlands, Norway, Spain,
Sweden, and the UK). The French cohort included
members of a health insurance plan for school and uni-
versity employees. Participants at the Spanish and Italian
centers (except Florence) included blood donors, mem-
bers of several health insurance programs, employees of
several enterprises, civil servants, and people from the
general population. In Utrecht and Florence, women
mainly participating in mammographic screening pro-
grams were recruited for the study. In Oxford, most of
the cohort consisted of “health-conscious” persons from
England, Wales, Scotland, and Northern Ireland, many
of whom were vegetarians. Participants were recruited
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from the general population in the other centers. The
cohorts of France, Norway, Utrecht, and Naples included
only women. All study participants provided written in-
formed consent. Ethical approval for this study was ob-
tained from the International Agency for Research on
Cancer review board and local participating centers.
Detailed information on the study design, methods,
and rationale of the EPIC cohort has been previously re-
ported [13, 14]. Upon recruitment, participants provided
medical, dietary, and lifestyle data during interviews and
via questionnaires, including information on alcohol use,
smoking status, physical activity, education, reproductive
history, breastfeeding, hormone use, and previous ill-
nesses. Diet over the previous 12months was assessed
using validated country-specific questionnaires [13], and
individual nutrient intakes were derived from foods in-
cluded in the dietary questionnaires through the stan-
dardized EPIC Nutrient Database [15]. To correct for
systematic under- or overestimation of dietary intake be-
tween the study centers, dietary values across centers
were scaled using an additive calibration model [16]. All
dietary variables used in this study were calculated by
using additive calibration.
For the present study, women with prevalent cancers
(except non-melanoma skin cancer) at study enroll-
ment (n = 20,477), women who were lost to follow-up
(n = 2557), pregnant women at study enrollment (n =
556), and women with missing data on diet, weight or
height, physical activity, or breastfeeding were excluded
from the analyses (n = 78,245). The latter exclusions
due to missing covariates comprised all participants
from Umeå, Sweden, and Norway, where physical
activity was not collected in sufficient detail as well as
participants from Bilthoven, the Netherlands, where
information on breastfeeding was not collected. Add-
itionally, in order to exclude implausible dietary in-
takes, participants within the lowest and highest 1% of
the cohort distribution of the ratio of total energy in-
take to estimated energy requirements were excluded
(n = 5033). Therefore, 260,151 women were finally in-
cluded in the analytical sample.
WCRF/AICR lifestyle score
A score reflecting the adherence to the World Cancer Re-
search Fund/American Institute for Cancer Research
(WCRF/AICR) cancer prevention recommendations was
constructed, as in previous studies [5, 17, 18]. Of the ten
recommendations (components) in the updated WCRF/
AICR report [19], the ones pertinent to healthy body
weight, physical activity, consumption of plant-based
foods, energy-dense foods, red and processed meat, and
sugary drinks and alcohol, as well as the recommendation
for breastfeeding, were used for the construction of the
score (see Additional file 1: Table S1). As in a previous
EPIC publication, the recommendation regarding supple-
ment use (due to lack of data) and the separate recom-
mendation pertinent to cancer survivors (not applicable in
our study population) were not used for the lifestyle score
in the present project [17].
Detailed information on the construction of the WCRF/
AICR lifestyle score for the EPIC cohort has previously
been reported [17]. In short, a score of 1 was assigned to
the corresponding component when a recommendation
was met. Intermediate scores (0.5 points) were assigned
when recommendations were partially met. The scoring
system was constructed such as that each recommenda-
tion would contribute equally to the total WCRF/AICR
lifestyle score. Since the “eat whole grains, vegetables,
fruit, and beans” recommendation contained two sub-
recommendations (fruit and vegetable consumption and
dietary fiber intake), the component score was calculated
as the average of the sub-recommendations’ score. The
scores obtained for each component were summed to cal-
culate the WCRF/AICR lifestyle score for each study par-
ticipant. The score ranged from 0 to 8, and higher scores
indicated greater agreement with the WCRF/AICR cancer
prevention recommendations. The score was additionally
categorized into three groups: category 1 (0 to 3 points),
category 2 (> 3 to ≤ 5 points), and category 3 (> 5 points).
The main difference between our WCRF/AICR lifestyle
score and the scores used previously in EPIC and other
studies [5, 17, 18] is the inclusion of the consumption of
sugary drinks as a separate recommendation. Previous
studies considered the consumption of sugary drinks as a
sub-recommendation, together with the consumption of
energy-dense foods (in order to capture the WCRF/AICR
recommendation: “Food and drinks that promote weight
gain. Limit consumption of energy-dense foods; avoid
sugary drinks”). We decided to include the consumption
of sugary drinks as a separate recommendation, in order
to be in concordance with the updated WCRF/AICR can-
cer prevention recommendations from 2018 [19] (see
Additional file 1: Table S1).
Of note, we decided to assign 1 point for adherence to
the WCRF/AICR recommendation on alcohol consump-
tion to individuals, who had reported moderate alcohol
consumption (≤ 10 g of ethanol intake per day), in
addition to non-consumers [5, 17]. This decision was
made to reduce the risk of reverse causality, given that
many previous studies have shown “sick quitter effects,”
i.e., a higher proportion of persons with impaired health
in the non-drinker category [20].
Outcome assessment
Women who developed first primary incident and histo-
logically confirmed BCIS between recruitment and the
latest date of complete information were considered as
cases. BCIS cases were identified through population
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cancer registries in Denmark, Italy, the Netherlands,
Spain, Sweden, and the UK. In France, Germany, and
Greece, a combination of methods was used including
health insurance records, cancer pathology registries,
and active follow-up of study participants and their next
of kin. The latest dates of complete information for BCIS
incidence varied among centers, ranging between 2008
and 2013. Cancer cases were coded according to the
10th Revision of the International Statistical Classifica-
tion of Diseases, Injuries, and Causes of Death and the
Second Revision of the International Classification of
Diseases for Oncology.
In situ tumors were further classified based on their
morphology as ductal carcinoma in situ (DCIS, morph-
ology code 8500/2) or lobular carcinoma in situ (LCIS,
morphology code 8520/2).
Statistical analyses
Categorical variables were presented by percentages
and continuous variables by arithmetic means and
standard deviations (SD) for descriptive purposes.
Missing covariate values were sporadic (0.1–6.8%,
depending on the covariate) and occurred in all par-
ticipating study centers. We used multiple imput-
ation with a fully conditional specification as
provided by PROC MI in SAS [21], and missing
values of the covariates (highest level of attained
education, smoking status, presence of chronic dis-
eases at recruitment, age at menarche, age at first
full-term pregnancy, ever use of oral contraceptive
pills, and ever use of menopausal hormone therapy)
were imputed on the basis of the distribution of age
at recruitment, total dietary energy consumption,
menopausal status, and all the individual compo-
nents of the WCRF/AICR lifestyle score and BCIS
diagnosis. Additionally, age at menarche, age at first
full-term pregnancy, and ever use of oral contracep-
tive pills, or ever use of menopausal hormone ther-
apy, were used to impute ever use of menopausal
hormone therapy and ever use of oral contraceptive
pills, respectively. The PROC MI procedure resulted
in five complete data sets. The five complete data
sets were then analyzed with Cox proportional haz-
ards regression, and the results for all were com-
bined with PROC MIANALYZE in SAS.
Cox proportional hazards regression was used to as-
sess the association between the WCRF/AICR lifestyle
score as well as its individual components and the risk
of BCIS development. Entry time was defined as the date
of a participant’s recruitment in the study and exit time
as the date of diagnosis of BCIS. Participants who were
not diagnosed with BCIS were censored on the date of
diagnosis of other cancers, except non-melanoma skin
cancer, or on the date of loss to follow-up, end of
follow-up, or death, whichever came first. All analyses
were stratified by age at recruitment (1-year intervals)
and center.
Two sets of covariates were evaluated for statistical ad-
justment. In model 1, we adjusted for the highest level
of attained education (none/primary school, technical/
secondary school, university degree), smoking status
(never smoker, former smoker, current smoker), and
total dietary energy consumption (kcal/day). Model 2
was additionally adjusted for a priori determined con-
founders including the presence of chronic diseases at
recruitment (type 2 diabetes, heart disease, and stroke;
yes, no), age at menarche (< 12 years, ≥ 12 to ≤ 15 years,
> 15 years), age at first full-term pregnancy (nulliparous,
< 21 years, ≥ 21 to ≤ 30 years, > 30 years), menopausal
status [premenopausal, perimenopausal, postmenopausal
(also including surgical postmenopausal)], ever use of
oral contraceptive pills (yes, no), and ever use of meno-
pausal hormone therapy (yes, no). The WCRF/AICR life-
style score was assessed both as a continuous and as a
categorical variable. BCIS was evaluated as a composite
outcome (i.e., DCIS, LCIS, and all other in situ lesions)
and by morphological subtypes (DCIS vs. LCIS). The re-
sults are presented as hazard ratios (HR) and corre-
sponding 95% confidence intervals (CI).
Given that BCIS is mainly diagnosed by mammo-
graphic screening, we conducted subgroup analyses
evaluating the association in centers where most women
were recruited via screening programs and in which
screening participation during follow-up was high (Ut-
recht [22] and Florence [23]; screening-recruited co-
horts) compared to the other centers. Due to potential
differential participation in mammographic screening
programs by education level, smoking status, age at re-
cruitment (< 50 vs. ≥ 50 years), and menopausal status,
we conducted analyses additionally stratified by these
factors. Moreover, given the differential associations ob-
served for some risk factors, especially obesity, by meno-
pausal status and use of menopausal hormone therapy
[6], we looked at the association of the individual com-
ponents of the WCRF/AICR lifestyle score and BCIS
risk, stratifying by menopausal status and menopausal
hormone therapy use. Sensitivity analyses were con-
ducted, excluding participants with less than 1 year of
follow-up (n = 1794). Analyses were conducted using
SAS version 9.4 (SAS Institute, Cary, NC). All statistical
tests were two-sided, and p values < 0.05 were consid-
ered statistically significant.
Results
After an overall median follow-up time of 14.9 years,
1277 BCIS (938 DCIS, 96 LCIS, 243 other in situ lesions)
cases were diagnosed in the EPIC cohort. Proportions of
BCIS to overall breast cancer cases varied between 4.3
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and 15.8% across the study centers (Additional file 1:
Table S2). As expected, the age-standardized incidence
rate of BCIS was higher in the screening-recruited co-
horts (EPIC-Florence and EPIC-Utrecht, 15.5 cases per
100,000 person-years) compared to the other centers
(10.2 cases per 100,000 person-years), with an overall
average incidence rate of 10.5 per 100,000 person-years.
A further description of the study population is shown
in Table 1. Women from the screening-recruited cohorts
were older, less likely to have a university degree, and
more likely to be former or current smokers, compared
to women recruited in the non-screening centers.
The associations between the WCRF/AICR lifestyle
score and BCIS risk are shown in Table 2. The WCRF/
Table 1 Baseline characteristics in the total study population
Total study population
(n = 260,151)
Screening-recruited cohorts
(n = 24,727)
Other centers
(n = 235,424)
WCRF/AICR lifestyle score, mean (SD) 4.5 (1.1) 4.5 (1.1) 4.5 (1.1)
Age at recruitment, mean (SD) 51.7 (9.9) 55.5 (7.2) 51.3 (10.0)
Highest level of attained education, %
None/primary school 30.4 31.1 30.3
Technical/secondary school 41.7 52.1 40.6
University degree 23.7 16.6 24.4
Unknown/missing 4.2 0.2 4.7
Smoking status, %
Never smokers 59.1 45.1 60.6
Former smokers 21.8 30.6 20.9
Current smokers 17.5 24.3 16.8
Unknown/missing 1.5 0.0 1.7
Chronic diseases at recruitment, %
Yes 3.3 4.5 3.2
Unknown 6.8 0.4 7.5
Menopausal status, %
Premenopausal 33.4 17.6 35.0
Postmenopausal 49.9 65.0 48.3
Perimenopausal 16.8 17.5 16.7
Ever use of oral contraceptive pills, %
Yes 56.7 57.7 56.6
Unknown 0.4 0.1 0.4
Ever use of menopausal hormone therapy, %
Yes 24.7 23.6 24.8
Unknown 6.0 0.1 6.6
Age at menarche, %
< 12 years 15.7 15.6 15.7
≥ 12 to ≤ 15 years 77.1 75.9 77.2
> 15 years 6.2 7.2 6.1
Unknown 1.0 1.3 1.0
Age at first full-term pregnancy, %
Nulliparous 15.6 13.9 15.8
< 21 years 11.7 6.3 12.3
≥ 21 to ≤ 30 years 63.9 69.1 63.4
> 30 years 8.6 10.7 8.4
Unknown 0.2 0.0 0.2
SD standard deviation, WCRF/AICR World Cancer Research Fund/American Institute for Cancer Research
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AICR lifestyle score was not significantly associated with
BCIS risk (HR = 0.98, 95% CI 0.93–1.03; per one unit of
increase in the WCRF/AICR lifestyle score, HRcat 3 vs. cat
1 = 0.98, 95% CI 0.80–1.22; in the multivariable models)
in the full EPIC cohort. A significant inverse BCIS risk
association for WCRF/AICR lifestyle score was observed
in the screening-recruited cohorts (HR = 0.85, 95% CI
0.73–0.99; per one unit of increase in the WCRF/AICR
lifestyle score in the multivariable model), but not in the
other centers (HR = 0.99, 95% CI 0.94–1.05; per one unit
of increase in the WCRF/AICR lifestyle score in the
multivariable model). While prespecified subgroup ana-
lyses of smoking status and menopausal status showed
similar associations as the overall analyses, the inverse
association between lifestyle score and BCIS risk was
more pronounced among women with lower education
level in the screening-recruited cohorts (Table 2). Asso-
ciations between lifestyle score and BCIS risk from ana-
lyses stratified by age at recruitment (< 50 vs. ≥ 50 years)
were similar in the two subgroups (data not shown).
Analyses by morphological subtype showed similar, non-
significant associations for DCIS (HR = 0.97, 95% CI
0.91–1.03) or LCIS risk (HR = 0.91, 95% CI 0.75–1.10;
per one unit of increase in the WCRF/AICR lifestyle
score in the multivariable model for the total study
population; Additional file 1: Table S3).
The mutually adjusted HRs for BCIS incidence as-
sociated with the individual components of the
WCRF/AICR lifestyle score are shown in Table 3. In
the overall study population, as well as in the analyses
stratified by recruitment mode, none of the compo-
nents of the score was significantly associated with
BCIS. In the analyses stratified by menopausal status
and menopausal hormone therapy use, BMI was in-
versely associated with BCIS risk in premenopausal
women (Additional file 1: Table S4).
Sensitivity analyses excluding women with less than 1
year of follow-up, or using the slightly different lifestyle
score previously used by Romaguera et al. in the EPIC
cohort [17], did not substantially modify our results
(data not shown).
Discussion
In the present large prospective study, we investigated
the association between adherence to the WCRF/AICR
cancer prevention recommendations and risk of BCIS.
Overall, we did not find an association between the
WCRF/AICR lifestyle score and BCIS risk. However,
subgroup analyses among women who were mostly re-
cruited via mammographic screening programs in the
EPIC centers in Florence and Utrecht, with high
screening participation rates during follow-up, did
show an inverse association.
To the best of our knowledge, even though no other
studies exist on lifestyle scores in relation to BCIS risk,
our findings are comparable to those of previous studies
assessing invasive or total (invasive and in situ tumors as
composite endpoint) breast cancer risk. The majority of
these studies have reported inverse associations between
the WCRF/AICR lifestyle score and invasive [both in
postmenopausal and in mixed (i.e., pre- and postmeno-
pausal) populations] [4, 17, 18, 24, 25] or total breast
cancer risk [5], with few exceptions [3, 26]. Particularly,
those studies on primarily postmenopausal breast cancer
risk that recruited participants via mammographic
screening programs [18] or adjusted for mammographic
screening attendance in their analyses [4] reported asso-
ciations of comparable magnitude to those found in our
study for the screening-recruited EPIC cohorts. Given
that BCIS is a mainly screen-detected cancer, the inverse
association observed in the screening-recruited cohorts
might suggest masking of a similar association in the
total population due to screening bias (i.e., women with
a more health-conscious lifestyle being more prone to
screening participation and screening-detected BCIS)
and undetected BCIS status at recruitment. To this end,
our overall analyses were limited by the fact that screen-
ing participation was not uniformly assessed in most
EPIC cohorts.
The lack of a statistically significant association be-
tween the individual components of the WCRF/AICR
lifestyle score and BCIS risk that we observed in the
present study is overall consistent with the findings from
studies on invasive breast cancer risk using similar
scores [18, 25–27], even though for some individual
components (e.g., alcohol consumption) associations
have been detected [4, 24, 27]. The inverse association
between BMI and BCIS risk in premenopausal women
in the present study is consistent with recently published
data from a pooling project, in which we took part with
EPIC [7]. By contrast, unlike in the NIH-AARP Diet and
Health Study [6], we did not observe a significant posi-
tive association between BMI and postmenopausal BCIS
among never users of menopausal hormone therapy, but
our results are in accordance with those of the Million
Women Study [8].
Our findings from the subgroup analyses in the
screening-recruited EPIC cohorts could suggest that a
combined healthy lifestyle (rather than individual
components alone) is important for the carcinogenetic
process in the breast. However, the lack of association
for individual components of the WCRF/AICR life-
style score in our analyses could also be due to the
relatively small proportion of the study population in
the screening-recruited EPIC cohorts (9.5% of the
total study population). Future large-scale studies with
more detailed information on mammographic
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screening attendance during follow-up and BCIS sta-
tus at recruitment are needed in order to investigate
the individual lifestyle factors in relation to BCIS risk
in more detail.
Given the agreement between our subgroup finding of
an inverse association between lifestyle score and BCIS
risk and those reported in other studies for invasive or
total breast cancer (i.e., simultaneously including
Table 3 Associations between adherence to individual WCRF/AICR cancer prevention recommendations and in situ breast cancer
risk
WCRF/AICR
cancer prevention
recommendation*
Total study population (n = 260,151) Screening-recruited cohorts (n = 24,727) Other centers (n = 235,424)
N cases/non-cases HR (95% CI) N cases/non-cases HR (95% CI) N cases/non-cases HR (95% CI)
Limit sugary drinks
0 189/39,589 Ref. 25/3537 Ref. 164/36,052 Ref.
0.5 799/160,657 0.95 (0.81–1.13) 103/15,276 1.01 (0.64–1.58) 696/145,381 0.94 (0.79–1.13)
1 289/58,628 0.96 (0.78–1.18) 31/5755 0.87 (0.48–1.57) 258/52,873 0.97 (0.77–1.21)
Breastfeed your baby
0 407/77,037 Ref. 48/6937 Ref. 359/70,100 Ref.
0.5 466/90,454 0.97 (0.82–1.14) 65/9253 1.02 (0.63–1.66) 401/81,201 0.96 (0.80–1.14)
1 404/91,383 0.99 (0.83–1.19) 46/8378 0.80 (0.48–1.35) 358/83,005 1.02 (0.85–1.23)
Limit alcohol
0 213/34,536 Ref. 37/4610 Ref. 176/29,926 Ref.
0.5 232/44,967 0.88 (0.73–1.06) 28/3820 0.94 (0.57–1.56) 204/41,147 0.88 (0.71–1.08)
1 832/179,371 0.88 (0.75–1.03) 94/16,138 0.75 (0.50–1.12) 738/163,233 0.90 (0.76–1.08)
Limit red and processed meat
0 530/98,891 Ref. 76/11,309 Ref. 454/87,582 Ref.
0.5 588/115,191 1.04 (0.92–1.18) 68/10,938 1.13 (0.79–1.60) 520/104,253 1.03 (0.90–1.18)
1 159/44,792 0.94 (0.75–1.17) 15/2321 1.31 (0.73–2.35) 144/42,471 0.90 (0.71–1.14)
Eat whole grains, vegetables, fruit, and beans
0 109/22,992 Ref. 6/735 Ref. 103/22,257 Ref.
0.25 191/36,549 1.07 (0.84–1.37) 18/2763 0.68 (0.26–1.74) 173/33,786 1.11 (0.87–1.43)
0.5 352/76,202 0.88 (0.69–1.12) 58/8787 0.61 (0.25–1.51) 294/67,415 0.90 (0.70–1.16)
0.75 405/79,341 1.00 (0.77–1.29) 50/7893 0.54 (0.21–1.41) 355/71,448 1.06 (0.81–1.39)
1 220/43,790 0.95 (0.70–1.30) 27/4390 0.41 (0.14–1.23) 193/39,400 1.04 (0.75–1.45)
Limit “fast foods”
0 138/31,684 Ref. 23/3294 Ref. 115/28,390 Ref.
0.5 787/153,617 1.12 (0.91–1.36) 109/16,473 1.21 (0.72–2.02) 678/137,144 1.11 (0.89–1.38)
1 352/73,573 1.01 (0.78–1.32) 27/4801 1.21 (0.59–2.48) 325/68,772 0.99 (0.74–1.30)
Be physically active
0 589/128,040 Ref. 52/8307 Ref. 537/119,733 Ref.
0.5 257/43,378 1.11 (0.95–1.29) 38/4523 1.30 (0.83–2.02) 219/38,855 1.08 (0.92–1.27)
1 431/87,456 1.00 (0.88–1.15) 69/11,738 0.88 (0.59–1.31) 362/75,718 1.03 (0.90–1.19)
Be a healthy weight
0 143/40,712 Ref. 22/3310 Ref. 121/37,402 Ref.
0.5 359/76,314 1.15 (0.95–1.40) 61/8668 1.06 (0.65–1.74) 298/67,646 1.16 (0.94–1.44)
1 775/141,848 1.09 (0.90–1.31) 76/12,590 0.87 (0.53–1.43) 699/129,258 1.13 (0.92–1.38)
Model adjusted for the highest level of attained education (none/primary school, technical/secondary school, university), smoking status (never smoker, former
smoker, current smoker), total energy intake (kcal/day), presence of chronic diseases at recruitment (yes/no), age at menarche (< 12 years, ≥ 12 to ≤ 15 years, >
15 years), age at first full-term pregnancy (nulliparous, < 21 years, ≥ 21 to ≤ 30 years, > 30 years), menopausal status (premenopausal, perimenopausal,
postmenopausal (also including surgical postmenopausal)), ever use of oral contraceptive pills (yes/no), and ever use of menopausal hormone therapy (yes/no).
Additionally, all individual components were adjusted for the remaining components of the WCRF/AICR lifestyle score. All analyses were stratified for center and
age at recruitment (1-year intervals). *Detailed information on the operationalization of the WCRF/AICR lifestyle score can be found in Additional file 1: Table S1
CI confidence interval, HR hazard ratio, WCRF/AICR World Cancer Research Fund/American Institute for Cancer Research
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invasive and in situ tumors) [5, 17, 18, 25], as well as
other overlapping risk factors between BCIS and invasive
tumors [8], BCIS and invasive breast cancer may be dis-
eases with etiological similarities. Of note, adherence to
the WCRF/AICR lifestyle score has been previously as-
sociated with lower mammographic density [28], a risk
factor for both invasive and in situ tumors. Thus, associ-
ations between pre-diagnostic lifestyle and risk of BCIS
as well as invasive cancer could suggest that lifestyle acts
at a relatively early stage of breast carcinogenesis. Poten-
tial mechanisms underlying the associations between
lifestyle and breast cancer could be effects of lifestyle on
basal inflammation, steroid hormone metabolism, and
insulin sensitivity, and studies suggest that people fol-
lowing the WCRF/AICR cancer prevention recommen-
dations have a more favorable biomarker profile (i.e.,
lower levels of circulating estrogen metabolites, inflam-
matory cytokines, and C-peptide), compared to those
who do not [29, 30].
The strengths of this study included the prospective
design and the substantial number of histologically
confirmed incident BCIS cases, but it also had some
limitations. Information on lifestyle habits was only
available from baseline and thus may not reflect the
long-term lifestyle habits of the study participants.
Furthermore, information on mammographic screen-
ing attendance was not available for large parts of our
study population. The fact that proportions of BCIS
to total breast cancer cases ranged between 4.3 and
15.8% across the centers of the EPIC cohort suggests
that screening participation but potentially also BCIS
registration were different across study sites. In this
context, it should be noted that we could not disen-
tangle the underlying reasons with our data. Tem-
poral and regional differences in BCIS reporting are
not expected to be differential among EPIC
participants with different lifestyle behaviors or char-
acteristics (e.g., education, smoking status), differential
detection bias, i.e., a differential individual likelihood
to participate in screening related to individual health
consciousness and socio-economic status cannot be
ruled out. Nevertheless, we were able to perform ana-
lyses restricted to women mainly recruited via orga-
nized mammographic screening programs at the EPIC
centers in Florence and Utrecht and reported the re-
sults from these analyses separately. While our main
objective was to evaluate the adherence to lifestyle
recommendations in relation to BCIS risk, we ac-
knowledge that more etiology-oriented analyses on
BCIS risk from EPIC and other cohorts are needed,
also taking into account morphological tumor sub-
types based on larger case numbers. Finally, as in any
observational study, we cannot exclude the possibility
of residual confounding.
Conclusions
In summary, women with a higher lifestyle score includ-
ing healthy body weight, regular physical activity, con-
sumption of a high-quality diet, breastfeeding, and
drinking a moderate amount of alcohol, if any, did not
have a statistically significant lower risk of BCIS com-
pared to participants who did not adhere to these
habits in the EPIC cohort. However, there was a statisti-
cally significant inverse association among participants
recruited via screening programs and with high screen-
ing participation during follow-up, suggesting that a true
inverse association between lifestyle habits and BCIS risk
in the overall cohort may have been masked by the lack
of information on screening attendance. The potential
inverse association between lifestyle and BCIS risk in
our subgroup analyses restricted to screening-recruited
EPIC cohorts is consistent with the inverse associations
between lifestyle scores and mammographic density as
well as breast cancer risk reported in previous studies.
These findings may indicate that BCIS and invasive
breast cancer have a similar risk factor profile. Add-
itional studies, with more detailed information on
screening participation, are required in order to validate
our findings.
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